Pharmaceuticals

Images

Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles And Recent Developments - Forecast To 2030

The global narcolepsy drugs market was valued at US$ 3,596 Million in 2023, and is projected to reach US$ 6,138 Million by 2030. Sodium oxybate segment dominates the global narcolepsy drugs market owing to its widespread usage in treating narcolepsy symptoms such as excessive daytime sleepiness and cataplexy. Sodium oxybate medications, such as Xyrem, have been widely prescribed and have demonstrated significant efficacy in managing these symptoms, leading to their dominant market position. 

Images

Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) And Pipeline Analysis – Global Forecast To 2024

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide. It is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR.

Images

United States Pain Management Therapeutics Market, Patients Volume, And 50 Company’s Pipeline Analysis (By Product, Indication, Phase Of Development)

The largest segment of the United States pain management market is the arthritis while pediatric pain is the smallest segment for the pain management. The cancer pain management market is the most rapidly growing segment of the United States pain management market.

Images

Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, And Pipeline Drugs Analysis To 2021

With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted to grow during the forecasting period. Alzheimer’s treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity, patent of leading drugs have expired.

Images

Global Biosimilars Market And Forecast (By Product Type, Applications, Country Wise & Companies) To 2021 And Biosimilars Approved & Pipeline Analysis

The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020.  With the continuous increasing demand for biologics, manufacturers are looking for novel strategies that will help them attain maximum returns on investment. Biosimilars are seen as the key weapon to curbing soaring healthcare costs globally.

Images

Renal Cell Carcinoma - Global Drugs Market Forecast And Pipeline Analysis To 2021

The global renal cell carcinoma drugs market is anticipated to cross US$ 4.3 Billion mark by 2021. There are many factors, like smoking, hypertension, unhealthy eating habits and family history, which increase the risk of occurrence of renal cell carcinoma.

Images

Global Alzheimer’s Disease Drugs Market And Pipeline Drugs Market Analysis To 2020

With the ageing population, the number of patients suffering from Alzheimers disease is predicted to grow during the forecast period. Alzheimer`s treatment is a high risk, high reward market. Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies.

Images

Global Prostate Cancer Therapeutics Market To 2020

The global market for prostate cancer therapeutics is increasing, driven primarily by the growth in the hormonal therapy markets. The main drivers for the prostate cancer market are the increase in the global aging population, innovation in drugs and developments in genomics and proteomics.

Images

Worldwide - Hepatitis C Drugs Market & Pipeline Drugs Analysis To 2019

The hepatitis C market is rapidly evolving as new launches prompt a significant paradigm shift in the treatment of the disease. In 2011, a breakthrough in HCV therapy was witnessed with the first two direct acting anti-HCV drugs (Incivek and Victrelis) came to market and were followed by the market approval of two additional anti-HCV drugs (Sovaldi and Olysio) in 2013.